<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715296</url>
  </required_header>
  <id_info>
    <org_study_id>NHL-007</org_study_id>
    <nct_id>NCT03715296</nct_id>
  </id_info>
  <brief_title>Lenalidomide Based Immunotherapy in the Treatment of DLBCL</brief_title>
  <official_title>Lenalidomide Based Immunotherapy Efficacy Related Molecular Biomarker in Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the efficacy related molecular biomarker of Lenalidomide plus RCHOP
      or RICE in the treatment of de novo or Refractory and Relapsed DLBCL patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide 25mg</intervention_name>
    <description>Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2－6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        De novo DLBCL patients / Relapse Refractory DLBCL patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically diagnosed as diffuse large b-cell lymphoma and may provide a desirable lymph
        node tissue sample (10 paraffin sections or rolls) or lymph node biopsy sample (15 paraffin
        sections or rolls)

        Previously treated with Lenalidomide plus RCHOP regimen in de novo DLBCL or Lenalidomide
        plus RICE regimen in relapse refractory DLBCL.

        No history of stem cell transplantation.

        Written informed consent.

        Exclusion Criteria:

        Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study.

        Clinically significant active infection.

        Impaired liver, renal or other organ function not caused by lymphoma, which will interfere
        with the treatment schedule.

        Any significant medical or psychiatric condition that might prevent the patient from
        complying with all study procedures.

        Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before
        enrollment.

        Patients who are pregnant or breast-feeding.

        HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weili Zhao, MD, PhD</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>Zhao.weili@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhong Zheng, MD</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>zheng_zhong89@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili ZHAO, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>zhao.weili@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Shu CHENG, MD, PhD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665251</phone_ext>
      <email>orenge@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Weili ZHAO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shu CHENG, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

